125 related articles for article (PubMed ID: 788722)
1. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
Rees ED; Hamilton RD; Kanner IF; Wasson S; Hearn T
Atherosclerosis; 1976 Sep; 24(3):537-46. PubMed ID: 788722
[TBL] [Abstract][Full Text] [Related]
2. A two-year crossover therapeutic trial with halofenate and clofibrate.
Dujovne CA; Azarnoff DL; Pentikainen P; Manion C; Hurwitz A; Hassanein K
Am J Med Sci; 1976; 272(3):277-84. PubMed ID: 797258
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
Krut LH; Seftel HC; Joffe BI
S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
[TBL] [Abstract][Full Text] [Related]
4. One-year trials with halofenate, clofibrate, and placebo.
Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
[TBL] [Abstract][Full Text] [Related]
5. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
[No Abstract] [Full Text] [Related]
6. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
Rottiers R; van Egmond J
Acta Clin Belg; 1975; 30(5):398-408. PubMed ID: 1221746
[No Abstract] [Full Text] [Related]
7. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Keller C; Wolfram G; Zöllner N
Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
Lisch HJ; Patsch J; Sailer S; Braunsteiner H
Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
[TBL] [Abstract][Full Text] [Related]
9. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Schapel GJ; Edwards KD
J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
Jain AK; Ryan JR; McMahon FG
N Engl J Med; 1975 Dec; 293(25):1283-6. PubMed ID: 171574
[TBL] [Abstract][Full Text] [Related]
12. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Cenedella RJ; Crouthamel WG
J Lipid Res; 1976 Mar; 17(2):156-66. PubMed ID: 1270931
[TBL] [Abstract][Full Text] [Related]
13. The metabolic spectrum of halofenate.
Ryan JR
Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
[TBL] [Abstract][Full Text] [Related]
14. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
[No Abstract] [Full Text] [Related]
15. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
Arntz HR; Klemens UH; Vollmar LJ; Lang PD
Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
[TBL] [Abstract][Full Text] [Related]
16. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Wolfram G; Keller C; Kilani C; Zöllner N
Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
[No Abstract] [Full Text] [Related]
17. Effect of halofenate on serum lipids.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
[No Abstract] [Full Text] [Related]
18. Clofibrate in type II hyperlipoproteinemia.
Ditzel J; Bang HO
Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of several hypolipidemic agents related to clofibrate.
Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
[No Abstract] [Full Text] [Related]
20. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
